Your browser doesn't support javascript.
loading
Application of Pharmacokinetic/Pharmacodynamic Modeling to Bridge Mouse Antitumor Efficacy and Monkey Toxicology Data for Determining the Therapeutic Index of an Interleukin-10 Fc Fusion Protein.
Yang, Zheng; Loy, James; Poirson, Brian; Dai, Yanshan; Rajendran, Surendran; Xu, Shihua; Spires, Vanessa; Gururajan, Murali; Lin, Zheng; Arbanas, Jaren; Carl, Stephen; Pace, Samantha; Wang, Yun; Mehl, John; Vasudevan, Krishna; Spires, Thomas; Novosiadly, Ruslan; Coker, Shodeinde; Perez, Raymond; Covello, Kelly; Morin, Paul; Graziano, Robert; Broz, Miranda; Lehman-McKeeman, Lois.
Afiliação
  • Yang Z; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, United States.
  • Loy J; Discovery Toxicology, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Cambridge, MA, United States.
  • Poirson B; Discovery Oncology, Bristol Myers Squibb, Princeton, NJ, United States.
  • Dai Y; Nonclinical Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, United States.
  • Rajendran S; Nonclinical Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, United States.
  • Xu S; Nonclinical Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, United States.
  • Spires V; Discovery Oncology, Bristol Myers Squibb, Princeton, NJ, United States.
  • Gururajan M; Discovery Oncology, Bristol Myers Squibb, Princeton, NJ, United States.
  • Lin Z; Discovery Biotherapeutics, Bristol Myers Squibb, Princeton, NJ, United States.
  • Arbanas J; Discovery Biotherapeutics, Bristol Myers Squibb, Princeton, NJ, United States.
  • Carl S; Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, United States.
  • Pace S; Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, United States.
  • Wang Y; Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, United States.
  • Mehl J; Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, United States.
  • Vasudevan K; Translational Medicine, Bristol Myers Squibb, Princeton, NJ, United States.
  • Spires T; Translational Medicine, Bristol Myers Squibb, Princeton, NJ, United States.
  • Novosiadly R; Translational Medicine, Bristol Myers Squibb, Princeton, NJ, United States.
  • Coker S; Oncology Early Clinical Development, Bristol Myers Squibb, Princeton, NJ, United States.
  • Perez R; Oncology Early Clinical Development, Bristol Myers Squibb, Princeton, NJ, United States.
  • Covello K; Oncology Early Clinical Development, Bristol Myers Squibb, Princeton, NJ, United States.
  • Morin P; Discovery Biotherapeutics, Bristol Myers Squibb, Princeton, NJ, United States.
  • Graziano R; Discovery Oncology, Bristol Myers Squibb, Princeton, NJ, United States.
  • Broz M; Discovery Oncology, Bristol Myers Squibb, Redwood City, CA, United States.
  • Lehman-McKeeman L; Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, United States.
Front Pharmacol ; 13: 829063, 2022.
Article em En | MEDLINE | ID: mdl-35795558
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça